Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / October 13, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) announced today that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market ("Nasdaq"). The Company will retain the "KDMN" ticker wit...
Which Penny Stocks Are On Your List? When it comes to penny stocks , you should be prepared for a road of volatility. These stocks under $5 can easily move 50% in any direction in a single day. Trading penny stocks could be difficult if you don’t take the time for it thou...
Kadmon (KDMN) has submitted a marketing application with the FDA for belumosudil (KD025), Rho-associated coiled-coil kinase 2 inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD).The FDA has granted Breakthrough Therapy Designation to belumosudil for th...
Application Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program NEW YORK, NY / ACCESSWIRE / September 30, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for be...
NEW YORK, NY / ACCESSWIRE / September 8, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatm...
NEW YORK, NY / ACCESSWIRE / September 2, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference ...
This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 08/17/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...
NEW YORK, NY / ACCESSWIRE / August 13, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Nancy Miller-Rich to its Board of Directors. "Nancy possesses an extensive, decades-long track record of business development and commercialization success in varying roles a...
Kadmon (NYSE: KDMN ) : Q2 GAAP EPS of -$0.17 misses by $0.03 . More news on: Kadmon Holdings, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
NEW YORK, NY / ACCESSWIRE / August 6, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2020. "Following positive topline results from the primary analysis of the ROCKstar pivotal trial of belum...
News, Short Squeeze, Breakout and More Instantly...
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadm...
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering...